Human study · Supplements / medicine · 4 Nov 2026
Two Michigan cardiologists list five questions before one-time gene editing is used for high cholesterol and other common diseases
Source: ScienceDaily
What the research found
ScienceDaily dated its page 3 November 2026. The feed clock falls on 4 November in Bangkok. The report covers a perspective in JAMA Internal Medicine by Eric D. Smith, M.D., and Venkatesh L. Murthy, M.D., Ph.D., at the University of Michigan. They argue that a one-time genomic treatment is a different decision from a daily medicine that can be changed or stopped. They list five checks: how serious the disease is, whether adjustable treatments already exist, whether the tissue can hold a lasting change, whether the delivery risk fits the disease, and whether safety can be watched for years in very large groups. They note that some existing gene therapies list above $1 million per patient, and that a rare harm can still affect many people if a treatment is given to millions. They mention early work on one-time lowering of LDL cholesterol. This paper is a clinical framework. It does not report a new LDL result. DOI 10.1001/jamainternmed.2026.4690. Not medical advice.
Evidence level: Human study. A study in people, but an association isn't proof of cause.
More supplements / medicine news
- In muscle cells grown from older adults, semaglutide and GIP did not directly shrink the fibers
- A BJSM thesis summary maps who moves into frailty and whether community exercise can reverse pre-frailty in older adults
- A BJSM thesis summary asks how endurance and resistance exercise change eye pressure in primary open-angle glaucoma
- In mice, the experimental drug KCL-286 reduced DNA breaks and brain inflammation in an Alzheimer's model
- In aged rats, two weeks of the experimental drug cinaciguat cut circulating amyloid-beta about in half and brought LDL down to youthful levels